<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31738155</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-5992</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Anti-cancer agents in medicinal chemistry</Title>
          <ISOAbbreviation>Anticancer Agents Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>325</StartPage>
          <EndPage>334</EndPage>
          <MedlinePgn>325-334</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1871520619666191019093558</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Chronic Lymphocytic Leukaemia (CLL) is an indolent disorder, which mainly affects older adults. Since the advent of chemoimmunotherapy, great progress has been made in its treatment. However, some patients develop a more aggressive form of the disease and are included in the group of high-risk CLL patients with a dismal prognosis and a need for new therapies.</AbstractText>
          <AbstractText Label="OBJECTIVE">Maltotriose-modified poly(propylene imine) dendrimers were presented as potential agents in targeted therapy for CLL in the murine xenograft model.</AbstractText>
          <AbstractText Label="METHODS">Tumour, brain and internal organs resected from NOD scid gamma mice were subjected to gross and histopathological evaluation.</AbstractText>
          <AbstractText Label="RESULTS">The results of ex vivo tissue examination indicated that open-shell glycodendrimers prevented/inhibited the spread of CLL into the brain and internal organs and its transformation into a more aggressive form.</AbstractText>
          <AbstractText Label="CONCLUSION">The results of the study have a potentially important impact on the design of future personalized therapies as well as clinical trials.</AbstractText>
          <CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ziemba</LastName>
            <ForeName>Barbara</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>GeneaMed LTD, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Laboratory Genetics, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sikorska</LastName>
            <ForeName>Hanna</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Bio-Assistance, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jander</LastName>
            <ForeName>Magdalena</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>GeneaMed LTD, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuncman</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathomorphology, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Danilewicz</LastName>
            <ForeName>Marian</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathomorphology, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Appelhans</LastName>
            <ForeName>Dietmar</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Leibniz Institute of Polymer Research Dresden, Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bryszewska</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borowiec</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Laboratory Genetics, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franiak-Pietryga</LastName>
            <ForeName>Ida</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>GeneaMed LTD, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Laboratory Genetics, Medical University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Moores Cancer Center, University of California, San Diego, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Anticancer Agents Med Chem</MedlineTA>
        <NlmUniqueID>101265649</NlmUniqueID>
        <ISSNLinking>1871-5206</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050091">Dendrimers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011126">Polypropylenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014312">Trisaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C443641">poly(propyleneimine)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>639K0T34IK</RegistryNumber>
          <NameOfSubstance UI="C008317">maltotriose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FA2DM6879K</RegistryNumber>
          <NameOfSubstance UI="D014740">Vidarabine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P2K93U8740</RegistryNumber>
          <NameOfSubstance UI="C024352">fludarabine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050091" MajorTopicYN="N">Dendrimers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011126" MajorTopicYN="N">Polypropylenes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014312" MajorTopicYN="N">Trisaccharides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014740" MajorTopicYN="N">Vidarabine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Poly(propylene imine)</Keyword>
        <Keyword MajorTopicYN="N">anticancer therapy</Keyword>
        <Keyword MajorTopicYN="N">chronic lymphocytic leukaemia</Keyword>
        <Keyword MajorTopicYN="N">dendrimer</Keyword>
        <Keyword MajorTopicYN="N">ex vivo</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
        <Keyword MajorTopicYN="N">tumour.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31738155</ArticleId>
        <ArticleId IdType="doi">10.2174/1871520619666191019093558</ArticleId>
        <ArticleId IdType="pii">ACAMC-EPUB-101641</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28280037</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>77</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.</ArticleTitle>
        <Pagination>
          <StartPage>2292</StartPage>
          <EndPage>2305</EndPage>
          <MedlinePgn>2292-2305</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-16-2832</ELocationID>
        <Abstract>
          <AbstractText>Mutations in tumor suppressor p53 remain a vital mechanism of tumor escape from apoptosis and senescence. Emerging evidence suggests that p53 dysfunction also fuels inflammation and supports tumor immune evasion, thereby serving as an immunological driver of tumorigenesis. Therefore, targeting p53 in the tumor microenvironment (TME) also represents an immunologically desirable strategy for reversing immunosuppression and enhancing antitumor immunity. Using a pharmacological p53 activator nutlin-3a, we show that local p53 activation in TME comprising overt tumor-infiltrating leukocytes (TILeus) induces systemic antitumor immunity and tumor regression, but not in TME with scarce TILeus, such as B16 melanoma. Maneuvers that recruit leukocytes to TME, such as TLR3 ligand in B16 tumors, greatly enhanced nutlin-induced antitumor immunity and tumor control. Mechanistically, nutlin-3a-induced antitumor immunity was contingent on two nonredundant but immunologically synergistic p53-dependent processes: reversal of immunosuppression in the TME and induction of tumor immunogenic cell death, leading to activation and expansion of polyfunctional CD8 CTLs and tumor regression. Our study demonstrates that unlike conventional tumoricidal therapies, which rely on effective p53 targeting in each tumor cell and often associate with systemic toxicity, this immune-based strategy requires only limited local p53 activation to alter the immune landscape of TME and subsequently amplify immune response to systemic antitumor immunity. Hence, targeting the p53 pathway in TME can be exploited to reverse immunosuppression and augment therapeutic benefits beyond tumoricidal effects to harness tumor-specific, durable, and systemic antitumor immunity with minimal toxicity. Cancer Res; 77(9); 2292-305. ©2017 AACR.</AbstractText>
          <CopyrightInformation>&#xa9;2017 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Miao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Celis</LastName>
            <ForeName>Esteban</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, Georgia. ycui@augusta.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA136828</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA157303</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA169133</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>53IA0V845C</RegistryNumber>
          <NameOfSubstance UI="C482205">nutlin 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28280037</ArticleId>
        <ArticleId IdType="mid">NIHMS858424</ArticleId>
        <ArticleId IdType="pmc">PMC5465961</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2832</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-16-2832</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9039259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor perspectives in biology. 2010;2(1):a001008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2827900</ArticleId>
            <ArticleId IdType="pubmed">20182602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature reviews Drug discovery. 2008;7(12):979&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19043449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo G, Marrero L, Rodriguez P, Del Valle L, Ochoa A, Cui Y. Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res. 2013;73(6):1668&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3602383</ArticleId>
            <ArticleId IdType="pubmed">23319800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, et al. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. Faseb J. 2011;25(7):2387&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3114529</ArticleId>
            <ArticleId IdType="pubmed">21471252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menendez D, Shatz M, Resnick MA. Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol. 2013;25(1):85&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23150340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis. 2014;35(8):1680&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123652</ArticleId>
            <ArticleId IdType="pubmed">24942866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes &amp; cancer. 2011;2(4):503&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3135644</ArticleId>
            <ArticleId IdType="pubmed">21779518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer cell. 2013;23(1):93&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23273920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature reviews Drug discovery. 2014;13(3):217&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24577402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19935675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell. 2015;27(4):450&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll D. Cancer and the Immune System: Basic Concepts and Targets for Intervention. Semin Oncol. 2015;42(4):523&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5595144</ArticleId>
            <ArticleId IdType="pubmed">26320058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in oncology. 2016;6:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4728205</ArticleId>
            <ArticleId IdType="pubmed">26858935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4601097</ArticleId>
            <ArticleId IdType="pubmed">17251933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, et al. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153(2):449&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3702034</ArticleId>
            <ArticleId IdType="pubmed">23562644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23157435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. Journal of the National Cancer Institute. 2013;105(4):256&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3576324</ArticleId>
            <ArticleId IdType="pubmed">23291374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer cell. 2015;28(6):690&#x2013;714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26678337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14704432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179(2):523&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2191382</ArticleId>
            <ArticleId IdType="pubmed">7507508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36(9):477&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3910494</ArticleId>
            <ArticleId IdType="pubmed">24145359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H, et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med. 2003;9(7):952&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong M, Lai MD, Lin YS, Lai MZ. Antagonism of p53-dependent apoptosis by mitogen signals. Cancer Res. 1999;59(12):2847&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10383145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17979839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell death and differentiation. 2014;21(1):69&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3857617</ArticleId>
            <ArticleId IdType="pubmed">23811849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer cell. 2014;26(5):638&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254577</ArticleId>
            <ArticleId IdType="pubmed">25446897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer cell. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5374862</ArticleId>
            <ArticleId IdType="pubmed">27424807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3587148</ArticleId>
            <ArticleId IdType="pubmed">22437938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499&#x2013;506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810498</ArticleId>
            <ArticleId IdType="pubmed">19342621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41(3):389&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4171711</ArticleId>
            <ArticleId IdType="pubmed">25238096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cubillos-Ruiz JR, Mohamed E, Rodriguez PC. Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. J Immunother Cancer. 2017;5:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5240216</ArticleId>
            <ArticleId IdType="pubmed">28105371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 2010;22(3):105&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2884069</ArticleId>
            <ArticleId IdType="pubmed">20226686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25838376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23579075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun. 2015;6:7114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4435831</ArticleId>
            <ArticleId IdType="pubmed">25968334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res. 2014;2(8):720&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24801836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takemura R, Takaki H, Okada S, Shime H, Akazawa T, Oshiumi H, et al. PolyI:C-Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector-Mediated Tumor Elimination In Vivo. Cancer Immunol Res. 2015;3(8):902&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25898986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1802742</ArticleId>
            <ArticleId IdType="pubmed">17295916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4588239</ArticleId>
            <ArticleId IdType="pubmed">26168215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27069014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23562161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov. 2016;6(1):71&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5036540</ArticleId>
            <ArticleId IdType="pubmed">26493961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menendez D, Lowe JM, Snipe J, Resnick MA. Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5308678</ArticleId>
            <ArticleId IdType="pubmed">27533082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012;72(16):3948&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3443562</ArticleId>
            <ArticleId IdType="pubmed">22673234</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23521677</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.</ArticleTitle>
        <Pagination>
          <StartPage>2467</StartPage>
          <EndPage>2475</EndPage>
          <MedlinePgn>2467-75</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1 α) is crucially involved in the development of osteolytic bone lesions in MM. Phenolic components of extra virgin olive oil are reported to have anti tumor activity. However, the underlying mechanisms and specific targets of extra virgin olive oil remain to be elucidated. In the present study, we investigated the effects of a recently isolated novel extra virgin olive oil polyphenol, oleocanthal, on the human multiple myeloma cell line ARH-77. Here we report that this natural compound has a remarkable in vitro activity by inhibiting MIP-1 α expression and secretion in MM cells. In addition, we also demonstrated that oleocanthal inhibits MM cells proliferation by inducing the activation of apoptosis mechanisms and by down-regulating ERK1/2 and AKT signal transduction pathways. This in vitro study suggests a therapeutic potential of oleocanthal in treating multiple myeloma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Scotece</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>SERGAS, Santiago University Clinical Hospital Research Laboratory 9 (NEIRID LAB: Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Institute of Medical Research (IDIS), Santiago de Compostela, 15706, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gómez</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conde</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gómez-Reino</LastName>
            <ForeName>J J</ForeName>
            <Initials>JJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lago</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>A B</ForeName>
            <Initials>AB</Initials>
            <Suffix>3rd</Suffix>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gualillo</LastName>
            <ForeName>O</ForeName>
            <Initials>O</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000447">Aldehydes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054405">Chemokine CCL3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081004">Cyclopentane Monoterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000069463">Olive Oil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010938">Plant Oils</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AC7QO6038O</RegistryNumber>
          <NameOfSubstance UI="C503534">oleocanthal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000447" MajorTopicYN="N">Aldehydes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054405" MajorTopicYN="N">Chemokine CCL3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081004" MajorTopicYN="N">Cyclopentane Monoterpenes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069463" MajorTopicYN="N">Olive Oil</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010938" MajorTopicYN="N">Plant Oils</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23521677</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867311320190006</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-20130315-17</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
